Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danny Woo

Nephrology Louisville, KY Medical Doctor

NPI 1710989884 CMS profile 350833

6400 Dutchmans Pkwy, Ste 250, Louisville, KY 40205

Open in the dashboard

General payments

$427,051

722 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danny Woo of Louisville, KY is reported in the CMS Open Payments database as having received $427,051 across 722 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,317 10
2024 General $71,478 70
2023 General $107,365 108
2022 General $65,562 100
2021 General $65,572 141
2020 General $45,805 124
2019 General $51,952 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danny Woo
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Danny Woo were reported at $19,317. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Danny Woo Nephrology median Middle half National median
2019 $51,952 $236 $90–$588 $163
2020 $45,805 $135 $46–$364 $114
2021 $65,572 $202 $67–$551 $132
2022 $65,562 $242 $77–$695 $149
2023 $107,365 $254 $84–$766 $160
2024 $71,478 $300 $99–$852 $164
2025 $19,317 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $253,965 270 payments
  2. AstraZeneca Pharmaceuticals LP $164,645 243 payments
  3. Amgen Inc. $1,028 23 payments
  4. Janssen Pharmaceuticals, Inc $818 9 payments
  5. Novartis Pharmaceuticals Corporation $711 9 payments
  6. GlaxoSmithKline, LLC. $587 7 payments
  7. Relypsa, Inc. $547 31 payments
  8. Horizon Therapeutics plc $458 25 payments
  9. Novo Nordisk Inc $388 4 payments
  10. Organogenesis Inc. $330 3 payments
  11. Other $3,575 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $331,761 160 payments
  2. Travel and Lodging $56,372 149 payments
  3. Consulting Fee $20,544 10 payments
  4. Food and Beverage $18,210 397 payments
  5. Education $165 6 payments
Products named General payments · program years 2019–2025
  1. JYNARQUE Nephrology $252,519 254 payments
  2. LOKELMA $163,341 220 payments
  3. XARELTO $684 7 payments
  4. FARXIGA $659 15 payments
  5. Veltassa $485 28 payments
  6. KRYSTEXXA $436 24 payments
  7. Otezla $380 4 payments
  8. LEQVIO $364 3 payments
  9. Puraply $330 3 payments
  10. JYNARQUE Nephrology $326 12 payments
  11. Other $6,121 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

39

Median for Internal Medicine: 777

Drug cost

$94

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 13 $43
Spironolactone Generic 13 $31
Atenolol Generic 13 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JYNARQUE
$70,353 — —
LEQVIO
$244 — —
AREXVY
$225 — —
VOQUEZNA
$196 — —
Inpefa
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

722 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record